Abstract
SummaryApocrine metaplastic change is a frequent change in breast pathology. Invasive carcinoma with apocrine differentiation of the breast has unconventional histology, immunohistochemical (IHC), and molecular profile. It has an Estrogen receptor (ER)/Progesterone receptor (PR) negative and an Androgen receptor (AR) positive profile. About 1/3 of cases can show Her2neu amplification through IHC or Fluorescence in situ hybridization (FISH). Lymphovascular invasion (LVI) and lymph node metastasis (LNM) are frequently observed and they often have poor pathological response to chemotherapy. Histologically and molecularly defined apocrine subtypes of breast cancer, although have considerable overlap, yet are different and discrete entities. The decision on using chemotherapy and targeted regimens in these lesions is still controversial which calls for more insight. This could be achieved by acquiring a standardized diagnostic practice, further research, and discussion.
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Abbasi F, Abbasi A, Hazrati Z. Histopathologic changes of non-tumoral breast tissue in patients with invasive carcinoma of breast. Int J Res App Basic Med Sci. 2019;5(2):116–20.
2. Akashi M, Yamaguchi R, Kusano H, Ogasawara S, Abe E, Obara H, et al. Androgen receptor expression is useful to predict the therapeutic effect in HER2-positive breast carcinoma. Breast Cancer Res Treat. 2020;184:277–85.
3. Alencar NNd, Souza DAd, Lourenço AA, Silva RR. Sebaceous breast carcinoma. Autopsy and Case Reports. 2022;12.
4. Astvatsaturyan K, Yue Y, Walts AE, Bose S. Androgen receptor positive triple negative Breast cancer: clinicopathologic, prognostic, and predictive features. PLoS ONE. 2018;13(6):e0197827.
5. Bane A. Ductal carcinoma in situ: what the pathologist needs to know and why. International Journal of Breast Cancer. 2013;2013.